Designing Living Materials

Expercy’s core advantage lies in a highly scalable, automated production process that reduces costs by 40% while delivering three transformative technology platforms:

1. Synchronous Therapeutic Systems: Featuring world-leading thermo-responsive phase-change technology (ConoSpina®), our materials inject as liquids to fill complex anatomical dead spaces before solidifying at body temperature. This provides unprecedented clinical predictability by synchronizing material degradation with natural tissue repair.

2. Bio-Active Regulation: Our high-flexibility dual-action films (DividPro®) go beyond physical barriers to actively regulate inflammatory responses, a breakthrough currently advancing toward U.S. FDA approval.

3. Regenerative Drug Delivery Platform: A precision synthesis platform that encapsulates bioactive molecules (e.g., BMP-2, analgesics) within biomaterials. This transforms implants into active healing vehicles, providing localized, sustained-release therapy.

By leveraging the animal health market (Ostevoke®) for early commercial validation, Expercy ensures de-risked, clinically superior solutions for high-value human healthcare needs.

1. Expercy will establish its U.S. Headquarters by Q1 2027, targeting California or Greater Boston. We aim to leverage proximity to the FDA and top-tier surgical centers, investing in robust MedTech ecosystems to foster local high-value jobs in Clinical Affairs and R&D.

2. Expercy executes a hybrid B2B partnership strategy in the U.S. We collaborate with top academic institutions and leading surgeons for robust clinical validation. For rapid commercialization, we partner with established medical device distributors to efficiently penetrate hospital networks, IDNs, and ASCs, accelerating the adoption of our programmable regenerative biomaterials platform.